JP2025526644A5 - - Google Patents
Info
- Publication number
- JP2025526644A5 JP2025526644A5 JP2025507205A JP2025507205A JP2025526644A5 JP 2025526644 A5 JP2025526644 A5 JP 2025526644A5 JP 2025507205 A JP2025507205 A JP 2025507205A JP 2025507205 A JP2025507205 A JP 2025507205A JP 2025526644 A5 JP2025526644 A5 JP 2025526644A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antineoplastons
- composition
- combination
- related genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263396104P | 2022-08-08 | 2022-08-08 | |
| US63/396,104 | 2022-08-08 | ||
| PCT/US2022/051695 WO2024035425A1 (en) | 2022-08-08 | 2022-12-02 | Compositions for and methods of precision cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025526644A JP2025526644A (ja) | 2025-08-15 |
| JP2025526644A5 true JP2025526644A5 (https=) | 2026-03-05 |
Family
ID=89852341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025507205A Pending JP2025526644A (ja) | 2022-08-08 | 2022-12-02 | 高精度のがん処置のための組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250387362A1 (https=) |
| EP (1) | EP4568663A1 (https=) |
| JP (1) | JP2025526644A (https=) |
| KR (1) | KR20250046322A (https=) |
| CN (1) | CN119947713A (https=) |
| AU (1) | AU2022474010A1 (https=) |
| CA (1) | CA3264480A1 (https=) |
| CL (1) | CL2025000366A1 (https=) |
| IL (1) | IL318887A (https=) |
| MX (1) | MX2025001546A (https=) |
| WO (1) | WO2024035425A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025217275A2 (en) * | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Immune cell targeted compositions and related methods |
| WO2026054617A1 (ko) * | 2024-09-09 | 2026-03-12 | 재단법인 아산사회복지재단 | 신장암 환자에서 방사선 치료 반응성을 예측하기 위한 유전자 패널 |
| CN119220612A (zh) * | 2024-11-29 | 2024-12-31 | 云南省肿瘤医院(昆明医科大学第三附属医院) | 一种增强肺部实体肿瘤趋化和抑瘤效果的car-t细胞构建方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2563797A1 (en) * | 2004-04-22 | 2005-11-10 | The University Of Utah | Kits and reagents for use in diagnosis and prognosis of genomic disorders |
| US10624869B2 (en) * | 2017-05-08 | 2020-04-21 | Stanislaw R. Burzynski | Methods for the treatment of recurrent glioblastoma (RGBM) |
-
2022
- 2022-12-02 KR KR1020257007699A patent/KR20250046322A/ko active Pending
- 2022-12-02 WO PCT/US2022/051695 patent/WO2024035425A1/en not_active Ceased
- 2022-12-02 CN CN202280100425.2A patent/CN119947713A/zh active Pending
- 2022-12-02 EP EP22955178.3A patent/EP4568663A1/en active Pending
- 2022-12-02 AU AU2022474010A patent/AU2022474010A1/en active Pending
- 2022-12-02 US US19/102,393 patent/US20250387362A1/en active Pending
- 2022-12-02 CA CA3264480A patent/CA3264480A1/en active Pending
- 2022-12-02 JP JP2025507205A patent/JP2025526644A/ja active Pending
- 2022-12-02 IL IL318887A patent/IL318887A/en unknown
-
2025
- 2025-02-06 MX MX2025001546A patent/MX2025001546A/es unknown
- 2025-02-07 CL CL2025000366A patent/CL2025000366A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gelibter et al. | Adjuvant chemotherapy in resected colon cancer: When, how and how long? | |
| JP2025526644A5 (https=) | ||
| Bellon et al. | Targeting Pim kinases in hematological cancers: molecular and clinical review | |
| Porru et al. | Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities | |
| Dhanyamraju | Drug resistance mechanisms in cancers: Execution of pro-survival strategies | |
| Song et al. | Challenges and perspectives on the development of small-molecule EGFR inhibitors against T790M-mediated resistance in non-small-cell lung cancer: miniperspective | |
| Ellis et al. | Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non–small cell lung cancer patients | |
| Rothenberg | Irinotecan (CPT-11): recent developments and future directions–colorectal cancer and beyond | |
| Gu et al. | CuS nanoparticles as a photodynamic nanoswitch for abrogating bypass signaling to overcome gefitinib resistance | |
| Wu et al. | Small molecular inhibitors for KRAS-mutant cancers | |
| Tirendi et al. | Colorectal cancer and therapy response: a focus on the main mechanisms involved | |
| US11504374B2 (en) | Compositions and methods for the treatment of a beta-catenin-associated disease or disorder | |
| Johnston et al. | Transcription factors and chromatin proteins as therapeutic targets in cancer | |
| Pocock et al. | Current and emerging therapeutic approaches for T‐cell acute lymphoblastic leukaemia | |
| US20250009736A1 (en) | Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and a parp inhibitor | |
| EP2501385B1 (en) | Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent | |
| Wang et al. | Current development of glioblastoma therapeutic agents | |
| Jachowski et al. | Modern therapies of nonsmall cell lung cancer | |
| Lv et al. | Cancer-associated fibroblasts: heterogeneity, tumorigenicity and therapeutic targets | |
| Bowles et al. | New phosphatidylinositol 3-kinase inhibitors for cancer | |
| IL318887A (en) | Composition and methods of precision cancer treatment | |
| Zuckerman et al. | siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide | |
| Schöffski et al. | Current role of topoisomerase I inhibitors for the treatment of mesenchymal malignancies and their potential future use as payload of sarcoma-specific antibody-drug conjugates | |
| CN114259566B (zh) | 一种基于破坏氧化还原平衡的抗肿瘤组合物及应用 | |
| Hao et al. | Current strategies for extensive stage small cell lung cancer beyond first-line therapy |